BCL2L1 and glioblastoma: Accordingly cisplatin [41], the pharmacological targeting of Bcl-2 and Bcl-x [22], proteasome inhibitors [40, 42, 43] and histone deacetylase inhibitors [44] have all been proven to be effective at establishing TRAIL sensitivity within GBM.